Tumor-Specific CD4+ T Cells Restrain Established Metastatic Melanoma by Developing Into Cytotoxic CD4– T Cells

Qiao Liu,Lisha Wang,Huayu Lin,Zhiming Wang,Jialin Wu,Junyi Guo,Shuqiong Wen,Ling Ran,Zhengliang Yue,Xingxing Su,Qing Wu,Jianfang Tang,Zhirong Li,Li Hu,Lifan Xu,Lilin Ye,Qizhao Huang

DOI: https://doi.org/10.3389/fimmu.2022.875718

IF: 7.3

2022-06-17

Frontiers in Immunology

Abstract:Cytotoxic CD8 + T cells are the main focus of efforts to understand anti-tumor immunity and immunotherapy. The adoptive transfer of tumor-reactive cytotoxic CD8 + T lymphocytes expanded and differentiated in vitro has long been considered the primary strategy in adaptive anti-tumor immunity, however, the majority of the transferred tumor antigen-specific CD8 + T cells differentiated into CD39 + CD69 + exhausted progenies, limiting its effects in repressing tumor growth. Contrarily, less attention has been addressed to the role of CD4 + T cells during tumorigenesis. Using a mouse model of metastatic melanoma, we found that transferring tumor-specific CD4 + T cells into recipients induces substantial regression of the established metastatic tumors. Notably, in vitro activated CD4 + T cells developed into cytotoxic CD4 - T cells in vivo and get exhausted gradually. The blockade of PD-L1 signaling resulted in an expansion of tumor specific CD4 + T cells, which could better control the established metastatic melanoma. Moreover, the tumor-specific memory CD4 + T cell can prevent mice from tumor metastasis, and the tumor-specific effector CD4 + T cells can also mitigate the established metastatic tumor. Overall, our findings suggest a novel mechanism of CD4 + T cells in curtailing tumor metastasis and confirm their therapeutic role in combination with PD-L1 blockade in cancer immunotherapy. Hence, a better understanding of cytotoxic CD4 - T cell-mediated tumor regression could provide an alternative choice for patients exhibiting suboptimal or no response to CD8 + T cell-based immunotherapies.

immunology